Skip to content
Menu

Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision

Vandana Singh 7 hours ago

BiotechHealth CareLarge Cap

Novo Nordisk unveils Phase 3 CagriSema weight-loss data and real-world Wegovy food-noise reductions at ObesityWeek 2026 in Washington, D.C.

Novo Nordisk (NYSE:NVO) presented trial and real-world data at ObesityWeek 2026 showing strong weight loss for investigational CagriSema and reduced food noise among Wegovy users.

CagriSema Delivers Weight Loss Across Lower Doses

On Saturday, Novo Nordisk unveiled primary Phase 3 REDEFINE 9 results in Washington, D.C., alongside simultaneous publication in The Lancet Diabetes & Endocrinology.

The trial tested CagriSema, a fixed-dose combination of cagrilintide and semaglutide, at doses below its 2.4 mg / 2.4 mg maximum.

Assuming full adherence, adults taking the 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg doses achieved 20.7% and 21.0% average weight loss at week 68, versus 2.0% for placebo. They also cut waist circumference by 17.2 cm and 17.5 cm, respectively, compared with 3.6 cm for placebo.

Under the treatment regimen estimand, those doses produced 19.4% and 18.6% weight loss versus 4.6% for placebo.

Early Responders and Quality-of-Life Gains

On Sunday, the company shared two post hoc analyses from the Phase 3 REDEFINE 1 trial of CagriSema 2.4 mg / 2.4 mg. About 67.8% of treated participants lost at least 5% of their body weight by week 8 and reached 25.4% mean weight loss at week 68, versus 17.8% for delayed responders.

At week 68, 73.1% reported meaningful physical function gains and 69.0% reported psychosocial improvements, topping placebo rates of 49.1% and 42.1%.

Novo Nordisk filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema 2.4 mg / 2.4 mg and expects a decision in the fourth quarter of 2026.

U.S. regulators have not approved CagriSema, and trials have not established its safety and efficacy.

Wegovy Reduces Food Noise in Real-World Studies

Novo Nordisk also presented Saturday findings from the retrospective SIGNAL and OCTANE studies using de-identified Ro telehealth data and a seven-item questionnaire tracking intrusive food thoughts.

In SIGNAL, 26,213 adults initiating semaglutide injections cut food-noise scores from a 2.72 baseline by 0.42 points at one month and 0.72 points at six months.

In OCTANE, adults starting oral semaglutide lowered food-noise scores by roughly 25% over three months, while 86.4% reported at least one improvement, including better-fitting clothing (67.5%) and healthier eating (51.6%).

NVO Price Action: Novo Nordisk shares were up 0.73% at $41.94 at the time of publication Monday, according to Benzinga Pro data.

Photo: Shutterstock

Read at benzinga.com